TY - CHAP
T1 - The Heterogeneity of Liver Cancer Metabolism
AU - Salazar, Javier
AU - Le, Anne
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021
Y1 - 2021
N2 - Primary liver cancer is the fourth leading cause of cancer death around the world. Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis patients [1], and the risk factors for developing HCC depend on the etiology [3] and the country of provenance [1]. There is an urgent need for an accurate diagnostic test given the high proportion of false positives and false negatives for alpha-fetoprotein (AFP), a common HCC biomarker [4]. Due to often being diagnosed in advanced stages, HCCrelated deaths per year have doubled since 1999 [3]. With the use of metabolomics technologies [5], the aberrant metabolism characteristics of cancer tissues can be discovered and exploited for the new biomarkers and new therapies to treat HCC [6, 7].
AB - Primary liver cancer is the fourth leading cause of cancer death around the world. Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis patients [1], and the risk factors for developing HCC depend on the etiology [3] and the country of provenance [1]. There is an urgent need for an accurate diagnostic test given the high proportion of false positives and false negatives for alpha-fetoprotein (AFP), a common HCC biomarker [4]. Due to often being diagnosed in advanced stages, HCCrelated deaths per year have doubled since 1999 [3]. With the use of metabolomics technologies [5], the aberrant metabolism characteristics of cancer tissues can be discovered and exploited for the new biomarkers and new therapies to treat HCC [6, 7].
KW - Glucose metabolism
KW - Glutamine metabolism
KW - Lipid metabolism
KW - Metabolic phenotypes
KW - Oncogenic heterogeneity
KW - Primary liver cancer
KW - Redox metabolism
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=85106407935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106407935&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-65768-0_9
DO - 10.1007/978-3-030-65768-0_9
M3 - Chapter
C2 - 34014539
AN - SCOPUS:85106407935
T3 - Advances in Experimental Medicine and Biology
SP - 127
EP - 136
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -